 NEW YORK, June 18, 2021 GLOBE NEWSWIRE -- TG Therapeutics, Inc. NASDAQ: TGTX, today announced data from two presentations evaluating TG-1701, the Companys investigational once-daily, oral BTK inhibitor, presented today during the 16th International Congress on Malignant Lymphoma ICML. One presentation evaluated TG-1701 preclinically and the other included Phase 1 data evaluating TG-1701 as a monotherapy and as a triple therapy in combination with ublituximab, the Companys novel glycoengineered anti-CD20 monoclonal antibody, and UKONIQ umbralisib, the Companys once-daily, inhibitor of PI3K-delta and CK1-epsilon in patients with front line or relapsedrefractory non-Hodgkins lymphoma NHL and chronic lymphocytic leukemia CLL. The Phase 1 data presented today were previously presented at the 2021 American Society of Clinical Oncology ASCO annual meeting and the 2021 European Hematology Association annual meeting. 